Kenichi Nogami

Beyond Next Ventures, Inc. (Beyond Next Ventures) is an Independent Venture Capital firm founded in 2014. Beyond Next Ventures, Inc. is headquartered in Tokyo.

Myoridge KK is a company based in Kyoto, Japan that specializes in selling cell products and developing support services for cell culture. The Japanese company also offers development support services for materials, operating methods, and equipment for all stages of the process. The company was founded in 2016 by Naohiro Makita, Shinichi Sueda.

Iviva Medical, Inc. develops autologous tissue to serve kidney diseases. The company was founded by Harald C Ott and is headquartered in Beverly, MA.

California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019.

Prime Movers Lab LLC (Prime Movers Lab) is a venture capital firm founded in 2018 by Dakin Sloss. The firm is headquartered in Jackson, Wyoming.

Arcline Investment Management LP (Arcline Investment) is a private equity firm founded in 2018 by Rajeev Joseph Amara. The firm is headquartered in San Francisco, California.

GlycoMira Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Salt Lake City, UT. The private company is dedicated to improving the standard of care and outcomes for patients with cancer and other inflammatory diseases. GlycoMira is developing a new class of innate immune system modulators based on polysaccharides that naturally occur within the body. The company's lead drug candidate, GM-1111, has demonstrated potential to address unmet needs in solid tumor treatment and supportive care. The CEO of the company is William P. Tew.

Elevian, Inc. develops medicines that restore youthful regenerative capacity. The company was founded by Mark J. F. Allen, Sebastian Giwa, Peter H. Diamandis, Brock C. Reeve, and Luis Alvarez and is headquartered in Allston, MA.